Dizziness butorphanol

Intranasal butorphanol may provide an alternative to frequent office or emergency department visits for injectable migraine therapies. Onset of analgesia occurs within 15 minutes of administration. Adverse effects include dizziness, nausea, vomiting, drowsiness, and taste perversion. It also a has the potential for dependence and addiction. 

As butorphanol is not orally active, reports of its transnasal administration are of interest. The most common adverse effects of transnasal butorphanol were dizziness, nausea and/or vomiting, headache, and drowsiness (SEDA-20, 83). Increased cardiac workload can also occur. 

---